OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Drug Discovery is 78. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Vaccine exposes tumours to immune cell attack	1579
A specific biomarker for insoluble tau	965
Targeting tumour-associated bacteria	738
A new path to targeted protein degradation?	720
Neutralizing Zika virus	629
The improving benefit–risk balance of phase I cancer trials	624
Tumour cells get a dendritic cell makeover	562
Glucose-sensitive insulin protects against hypoglycaemia	534
Promoting tissue repair after heart attack	449
Hypoimmune iPSCs escape immune detection	438
Lipid nanoparticle ferries therapeutic mRNA to the placenta	437
New antibiotic for urinary tract infections nabs FDA approval	414
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	413
FDA new drug approvals in Q1 2023	397
Apolipoprotein L2 inhibitor mitigates fibrosis	396
FDA approves second TTR stabilizer for cardiac amyloidosis	394
Targeting drug-resistant glioblastoma	383
Degrading cell-free DNA to prevent recurrent stroke	379
Target identification and assessment in the era of AI	356
AI serves up target and inhibitor for lung fibrosis	317
2022 FDA approvals	316
FDA approves a c-MET-targeted ADC for lung cancer	305
Small-molecule discovery through DNA-encoded libraries	293
Targeting the Hippo pathway in cancer	279
Chemical engineering of CRISPR–Cas systems for therapeutic application	257

Anti-tau antibody stumbles in phase II Alzheimer trial	256
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	256
mRNA vaccines for infectious diseases — advances, challenges and opportunities	234
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	231
Increasing the potency of T cell therapies	225
Small molecule improves muscle function in myasthenia gravis	216
Pushing both sides of the drug pricing aisle	216
TCR-engineered T cells get personal	204
R&D re-balancing act	202
Inhibiting ASGR1 boosts cholesterol removal	201
2025’s FDA approvals by regulatory designations	195
Rewired proteostasis in KRAS inhibitor resistance	192
An allosteric site on cereblon	185
Mimicking the health benefits of exercise	182
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	182
Host-directed antiviral blocks SARS-CoV-2 entry	181
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	178
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	166
Base editors hit the clinic	161
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	152
Combating antimicrobial resistance in malaria, HIV and tuberculosis	148
A peptide-guided strategy for kinase activation	146
Amylin takes another shot at the obesity prize	146
FDA new drug approvals in Q2 2023	145
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	145
A renaissance in targeting the PI3K/AKT/mTOR pathway	140
The significance of blockbusters in the pharmaceutical industry	139
Roads and detours for CAR T cell therapy in autoimmune diseases	135
The antibody–drug conjugate landscape	135
Antibody–drug conjugates come of age in oncology	130
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	130
Multi-TACs target solid tumours	125
Immunology on the brain	119
Reducing IL-2 toxicity	118
Gut metabolite mediates nerve repair	118
Agonist antibody lowers blood pressure	115
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	109
Neglected tropical diseases go global	109
Monkeypox mRNA vaccine protects mice and macaques	109
FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease	108
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	107
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	105
Targeting the ECM in melanoma	99
Redirecting mast cells for antigen-specific cancer immunotherapy	98
Designing G-protein-selective allosteric modulators	95
Ribosome inhibitor combats bacterial drug resistance	95
LRRK2-targeted Parkinson disease drug advances into phase III	93
The European Innovation Network as a hub for medicines innovation in Europe	91
Anti-IL-11 antibody shows anti-ageing properties	89
Realizing the potential of agonistic antibody immunotherapy	86

Frameworks for transformational breakthroughs in RNA-based medicines	81
Avidity in antibody effector functions and biotherapeutic drug design	81
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	81